We are live on ! Find out more
Prosight Management

Prosight Management Portfolio holdings

AUM $515M Turnover 48.89%
1-Year Est. Return 2.95%
This Fund
S&P 500
This Quarter Est. Return
+6.58%
1 Year Est. Return
-2.95%
3 Year Est. Return
+53.41%
5 Year Est. Return
-10.05%
10 Year Est. Return
–
AUM
$160M
AUM Growth
+$37.8M
Cap. Flow
+$30.7M
Cap. Flow %
19.19%
Top 10 Hldgs %
54.86%
Holding
54
New
17
Increased
15
Reduced
14
Closed
8
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.8 years

Sector Composition

Rank Sector Weight
1 Healthcare 95.1%
2 Industrials 2.39%
3 Miscellaneous 1.27%
4 Energy 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
PRTA icon
1
Prothena
PRTA
$429M
$21.7M 13.57%
422,000
-178,000
-30% -$5.55M
2020 Q3
3 quarters
ALBO
2
DELISTED
Albireo Pharma Inc
ALBO
$10.4M 6.49%
295,080
+124,728
+73% +$4.06M
2018 Q3
11 quarters
ARNA
3
DELISTED
Arena Pharmaceuticals
ARNA
$9.34M 5.84%
137,000
+31,172
+29% +$2.03M
2018 Q1
13 quarters
HAE icon
4
Haemonetics
HAE
$5.59B
$8.93M 5.58%
+134,000
New +$9.48M
2021 Q2
0 quarters
CUE icon
5
Cue Biopharma
CUE
$34.6M
$7.34M 4.59%
21,012
+2,453
+13% +$951K
2019 Q4
6 quarters
EHC icon
6
Encompass Health
EHC
$13.2B
$6.87M 4.29%
110,616
-15,084
-12% -$1.01M
2020 Q1
5 quarters
ALDX icon
7
Aldeyra Therapeutics
ALDX
$40.5M
$6.74M 4.22%
595,239
+121,793
+26% +$1.46M
2018 Q4
10 quarters
KZR icon
8
DELISTED
Kezar Life Sciences
KZR
$5.56M 3.48%
102,370
+27,339
+36% +$1.55M
2021 Q1
1 quarter
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$136B
$5.46M 3.42%
27,100
-11,250
-29% -$2.35M
2020 Q4
2 quarters
XCUR icon
10
Exicure
XCUR
$6.81M
$5.4M 3.38%
24,000
+22,161
+1,205% +$5.81M
2021 Q1
1 quarter
ZGNX
11
DELISTED
Zogenix
ZGNX
$5.28M 3.3%
305,788
+110,788
+57% +$2.04M
2020 Q1
5 quarters
ZBH icon
12
Zimmer Biomet
ZBH
$19.6B
$5.07M 3.17%
32,445
+10,612
+49% +$1.72M
2018 Q3
11 quarters
LKFT icon
13
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.25B
$4.96M 3.1%
72,000
+5,581
+8% +$426K
2021 Q1
1 quarter
CNVY
14
DELISTED
Convey Health Solutions Holdings
CNVY
$4.67M 2.92%
+410,412
New +$4.75M
2021 Q2
0 quarters
KALV icon
15
DELISTED
KalVista Pharmaceuticals
KALV
$4.34M 2.71%
+181,171
New +$4.74M
2021 Q2
0 quarters
MGTX icon
16
MeiraGTx Holdings
MGTX
$813M
$4.24M 2.65%
273,523
-18,421
-6% -$263K
2019 Q3
7 quarters
RCM icon
17
DELISTED
R1 RCM
RCM
$3.82M 2.39%
+171,817
New +$4.15M
2021 Q2
0 quarters
MORF icon
18
DELISTED
Morphic Holding
MORF
$3.69M 2.31%
64,292
+59,090
+1,136% +$3.25M
2021 Q1
1 quarter
IOVA icon
19
Iovance Biotherapeutics
IOVA
$3.46B
$3.61M 2.26%
+138,886
New +$3.61M
2021 Q2
0 quarters
MTCR
20
DELISTED
Metacrine
MTCR
$3.3M 2.07%
869,082
+564,597
+185% +$2.33M
2020 Q3
3 quarters
PRQR icon
21
ProQR Therapeutics
PRQR
$155M
$2.83M 1.77%
420,000
-30,165
-7% -$195K
2020 Q4
2 quarters
QSI icon
22
Quantum-Si
QSI
$235M
$2.79M 1.74%
+227,391
New +$2.38M
2021 Q2
0 quarters
UNH icon
23
UnitedHealth
UNH
$314B
$2M 1.25%
5,000
-1,000
-17% -$399K
2021 Q1
1 quarter
LHCG
24
DELISTED
LHC Group
LHCG
$1.98M 1.24%
9,888
+1,105
+13% +$222K
2020 Q4
2 quarters
AUPH icon
25
Aurinia Pharmaceuticals
AUPH
$2.03B
$1.68M 1.05%
130,000
-230,834
-64% -$2.94M
2020 Q2
4 quarters

Similar funds

Prosight Management's Q2 2021 Portfolio in Review

As of Q2 2021, Prosight Management held 54 positions worth $160M, up 31% from $122M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Prosight Management deployed $30.7M of net new capital in Q2 2021, opening 17 new positions and adding to 15 existing holdings. Its largest new stake was Haemonetics: 134,000 shares worth $8.93M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier, followed by Industrials and Miscellaneous.

On the sell side, the largest reduction was Prothena, an estimated $5.55M trimmed.

  • Prosight Management's largest Q2 2021 buy was Haemonetics: 134,000 shares worth $8.93M.
  • Prosight Management added most to Exicure in Q2 2021, an estimated $5.81M increase.
  • Prosight Management's biggest Q2 2021 reduction was Prothena, cutting an estimated $5.55M.
  • Prosight Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $6.04M.
  • Prosight Management's ten largest holdings make up 55% of its $160M portfolio in Q2 2021.
  • Prosight Management opened 17 new positions and closed 8 in Q2 2021.
  • Prosight Management's portfolio value rose 31% quarter-over-quarter to $160M.

Based on Prosight Management's 13F filing for Q2 2021, filed 13 Aug 2021.